GBA1 and Parkinson disease: Ambroxol treatment significantly reduced dihydroethidium oxidation rate in Gaucher disease [median dihydroethidium oxidation rate ΔRFU 0.05 (0.028–0.11) versus 0.027 (0.014–0.037) with ambroxol, Mann-Whitney U-test P = 0.004], Parkinson’s disease with GBA mutation [ΔRFU 0.06 (0.04–0.8) versus 0.03 (0.017–0.044), P = 0.001] and control [ΔRFU 0.04 (0.024–0.06) versus 0.026 (0.02–0.03), P = 0.028] lines (Fig. 3B).